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elidong2004@yahoAbstract Activation of cardiac sympathetic afferent reﬂex results in the increase of sympathetic
activity. Serotonin (5-HT) activates cardiac sympathetic afferent through stimulating 5-HT3
receptors, the aim of present study is to test whether 5-HT3 receptor antagonists protect against
cardiac hypertrophy. Cardiac hypertrophy induced by TAC for 4 weeks in mice was signiﬁcantly
inhibited by administration of 5-HT3 receptor antagonists, ondansetron (2.5 mg/kg, ip.) or
tropisetron (2.5 mg/kg, ip.). Histological analysis revealed that the increased cardiac ﬁbrosis in
hypertrophic heart was relieved by ondansetron or tropisetron treatment. Ondansetron or
tropisetron reduced the elevated plasma level of noradrenalin in mice with cardiac hypertrophy.
Ondansetron and tropisetron had no effect on cardiomyocte hypertrophy induced by phenylephrine
treatment in vitro. Finally, we took tropisetron as the representative drug and examined the effects
of tropisetron on the desensitization of cardiac b-adrenergic receptor in rat treated with abdominal
aortic banding (AB). Results showed that tropisetron restored the desensitization of cardiac
b-adrenergic receptor in AB-treated rats. In conclusion, 5-HT3 receptor antagonists protected
against cardiac hypertrophy and restored the desensitization of cardiac adrenergic responsiveness,
the mechanism in which may be through reducing the sympathetic activity.
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5-HT3 receptor antagonists protect against cardiac hypertrophy 171. Introduction
Cardiac hypertrophy involves a remodeling process of heart in
response to diverse pathological stimuli. Although considered
as a compensatory mechanism to maintain cardiac output
under conditions of overload, cardiac hypertrophy eventually
leads to heart failure and death1–3. Sympathetic activation is
an important pathological factor in promoting heart hyper-
trophy to heart failure and the mechanism includes activation
of renin–angiotensin system4,5, induction of cardiomyocyte
apoptosis6,7, enhancement of cardiac oxidative stress8, etc.
Therefore, antagonism of sympathetic nervous system is a
valuable therapeutic method for cardiac hypertrophy and
heart failure.
Serotonin (5-hydroxytryptamine, 5-HT), a neurohormone,
is involved in a range of physiological or pathophysiological
functions. 5-HT receptors include seven subtypes (5-HT1–7).
All other 5-HT receptors are G-protein coupled receptors,
with the exception of the 5-HT3 receptor, which is a ligand-
gated ion channel. 5-HT3 receptor plays an important role in
activation of cardiac sympathetic afferent9,10. Cardiac sympa-
thetic afferent reﬂex is a sympathoexcitatory reﬂex. The
activation of this reﬂex results in an increase of sympathetic
activity, which is responsible for the deteriorative progression
of cardiac hypertrophy and heart failure11. Furthermore,
activation of 5-HT3 receptors enhances noradrenaline
release12,13. The above knowledge indicates that 5-HT3 recep-
tor might be a target for inhibition of sympathetic activation,
herein, it is anticipated that 5-HT3 receptor antagonists would
protect against cardiac hypertrophy.2. Materials and Methods
2.1. Animals
Kunming mice (22–26 g) and Wistar rats (220–250 g) were
used. The animals were kept under standard animal room
conditions (temperature 2171 1C; humidity 55–60%) with
food and water continuously available for 1 week before the
experiment. All the experimental procedures were approved by
the Institutional Animal Care and Use Committee of Harbin
Medical University, China.2.2. Establishment of pressure-overload cardiac hypertrophy
and drug treatment in mice
The pressure-overload cardiac hypertrophy model was estab-
lished with mice. Detailed methods have been described in our
previous study14. Three days after operation of transverse
aortic constriction (TAC), the mice were randomly divided
into four groups, sham group, TAC model group, TAC model
treated with ondansetron (Ond) and tropisetron (Tro), named
as TACþOnd and TACþTro. Three days after operation,
ondansetron (2.5 mg/kg) and tropisetron (2.5 mg/kg) were
administered by intraperitoneal injection daily. After 4 weeks,
surviving animals were sacriﬁced, the plasma was collected
and the heart was quickly excised and weighed in cold buffer
(4 1C). The left ventricle was ﬁxed in paraformaldehyde for
histological analysis or rapidly frozen in liquid nitrogen and
stored at 80 1C for subsequent Western blot analysis.2.3. Determination of plasma noradrenaline level
Plasma levels of noradrenaline were measured using noradre-
naline research elisa Kit (BA 10-5200) (Labor Diagnostika
Nord GmbH&Co KG, Nordhorn, Germany) according to the
procedure speciﬁcation.
2.4. Preparation of primary rat cardiomyocytes
Detailed methods are described in our previous study14.
Brieﬂy, cardiomyocyte cultures were prepared by dissociation
of 1-day-old neonatal rat (Wistar) hearts and were differen-
tially plated to remove ﬁbroblasts. To induce the hypertrophic
response, phenylephrine (PE) was added to cardiomyocyte
cultures at 50 mM. The culture media containing PE was
changed every 12 h for a period of 72 h. Ondansetron
(50 mg/L) and tropisetron (20 mg/L) were present in the culture
medium. The doses of ondansetron and tropisetron were
referenced to the plasma concentrations in human15,16.
Cardiomyocytes were prepared for immunocytochemistry.
Monoclonal antibody against sarcomeric a-actinin (Sigma)
was added at dilutions of 1:200. Nuclear staining was
performed with 1.3 mM bisbenzimide (Sigma). The relative
surface area of the cell was calculated from the number of
pixels by using Image-Pro Plus Version (5.0.1).
2.5. Pressure analysis in anesthetized rats with abdominal
aortic banding (AB)
The rats were subjected to abdominal aortic banding as
described17. Rats were anesthetized with an intraperitoneal
injection of 300 mg/kg of chloral hydrate. The suprarenal portion
of the aorta was exposed and a blunted 22-gage needle placed
adjacent to the aorta. A ligature (5-0 silk) was tied around both
the aorta and the needle. The needle was then removed, leaving
the internal diameter of the aorta approximately equal to that
of the needle. Sham-operated animals had an untied ligature
placed in the same location. One day after surgery, animals were
randomized to three groups: sham, aortic banding (AB),
ABþtropisetron (1.25 mg/kg daily). Forty days after treatment,
rats were anesthetized and blood pressure was measured via a
polyethylene catheter inserted left ventricle through the right
carotid artery. The catheter was connected to a pressure transdu-
cer (Model YH-4; Institute of Space Medical-Engineering, China)
connected to a multichannel acquisition and analysis system
(Model BL-420E, Taimeng Technology Instrument, Chengdu,
China). After 20 min stable recording, dobutamine (0.8 mg/kg)
was injected (iv) to test the response of blood pressure to the
stimulation of b-adrenergic receptor.
2.6. Histological analysis
The tissue samples were embedded in parafﬁn and subjected to
standard hematoxylin and eosin (HE) staining or masson’s
trichrome staining.
2.7. Data analysis
Data are presented as mean7SEM. Signiﬁcance was determined
using one-way ANOVA in SigmaStat Analysis Software.
Po0.05 was considered signiﬁcant.
Figure 2 (A) Representative ﬁelds of masson’s trichrome stained
heart sections in sham, TAC, TACþOnd, TACþTro animals.
(B) The summarized data showed that TAC-induced cardiac
interstitial ﬁbrosis was inhibited by ondansetron and tropisetron
treatment. Po0.01 vs sham; ##Po0.01 vs TAC. TAC, trans-
verse aortic constriction; Ond, ondansetron; Tro, tropisetron.
n means the number of sections. The sections in each group were
from 3 hearts. Fibrosis was colored blue.
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3.1. 5-HT3 receptor antagonists protect against pressure
overload-induced cardiac hypertrophy in mice
There was no difference of the body weight of animals among
sham, TAC, TACþOnd and TACþTro groups when the
animals were sacriﬁced four weeks after surgery (Fig. 1A).
TAC induced signiﬁcant increases of the heart weight and left
ventricle weight and these increases were signiﬁcantly inhibited
by the treatment of two 5-HT3 receptor antagonists, ondanse-
tron and tropisetron (Figs. 1B and C). Compared with the
sham group, the heart weight and left ventricle weight of
animals in TACþOnd and TACþTro were still higher,
although ondansetron and tropisetron showed inhibitory
effects on cardiac hypertrophy (Figs. 1B and C). The results
of heart weight index and left ventricle weight index coincided
with the results of heart weight and left ventricle weight
(Figs. 1D and E).
As shown in Fig. 2A, the representative masson’s trichrome
staining showed that TAC induced marked cardiac ﬁbrosis,
which was signiﬁcantly inhibited by the treatment of ondanse-
tron and tropisetron, the summarized data was shown in
Fig. 2B. Because the increase of cardiac ventricle pressure
inﬂuences the reﬂux of pulmonary vein, therefore, we also
observed the lung weight. TAC resulted in the increased lung
weight and the lung weight index, which were inhibited by the
treatment of ondansetron and tropisetron. The representative
HE stainings of lung tissues and the analyzed data were shown
in Fig. 3.
3.2. 5-HT3 receptor antagonists have no effect on
cardiomyoctes hypertrophy induced by phenylephrine treatment
in vitro
In order to exclude the possibility that 5-HT3 receptor
antagonists inhibit cardiac hypertrophy through the directFigure 1 5-HT3 receptor antagonists, ondansetron and tropisetron, protect against pressure overload-induced cardiac hypertrophy in
mice. (A) Comparison of body weight in each group. (B) Comparison of heart weight in each group. (C) Comparison of left
ventricle weight in each group. (D) Comparison of heart weight/body weight (HW/BW) in each group. (E) Comparison of left
ventricle weight/body weight (LVW/BW) in each group. TAC, transverse aortic constriction; BW, body weight; HW, heart weight;
LVW, left ventricle weight; Ond, ondansetron; Tro, tropisetron. Po0.01 vs sham; #Po0.05, ##Po0.01 vs TAC; yyPo0.01 vs
sham.
Figure 3 (A) Representative ﬁelds of HE stained lung sections in
sham, TAC, TACþOnd, TACþTro animals. (B) The summarized
data showed that TAC-induced lung weight increase was inhibited by
ondansetron and tropisetron treatment. LW, lung weight; BW, body
weight; Po0.01 vs sham; ##Po0.01 vs TAC. TAC, transverse
aortic constriction; Ond, ondansetron; Tro, tropisetron.
Figure 4 5-HT3 receptor antagonists, ondansetron and tropisetron,
have no effect on cultured cardiomyocytes hypertrophy induced by
phenylephrine treatment in vitro. (A) The representative photographs
of cardiomyocytes with immunohistochemical staining. Cardiomyo-
cytes were identiﬁed ( 200) with a-actinin antibody (red signal) and
nuclei were stained with bisbenzamide (blue). (B) Comparison of cell
area in each group. (C) Comparison of b-MHC mRNA expression
in each group. PE, phenylephrine; Ond, ondansetron; Tro, tropise-
tron. Po0.01 vs control.
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receptor antagonists on cardiomyoctes hypertrophy induced
by phenylephrine treatment in vitro. As shown in Fig. 4,
ondansetron or tropisetron did not inhibit the increased cell
area and elevated b-MHC mRNA level induced by pheny-
lephrine treatment, suggesting that 5-HT3 receptor antagonists
have no direct inhibitory effects on cardiomyocte hypertrophy.
Previous study reported that tropisetron inhibited the tran-
scriptional activity of NFAT18, the factor involved in pheny-
lephrine induced cardiomyocte hypertrophy. However, in their
study, the concentration of tropisetron reached 50 mg/mL,
which was much higher than the clinical concentration15,16.Figure 5 (A) 5-HT3 receptor antagonists, ondansetron and
tropisetron, reduce the elevated plasma level of NA in cardiac
hypertrophy mice. Po0.05 vs sham; ##Po0.01 vs TAC. (B)
Ondansetron or tropisetron treatment does not change the plasma
NA level in normal mice. TAC, transverse aortic constriction;
Ond, ondansetron; Tro, tropisetron; NA, noradrenalin.3.3. 5-HT3 receptor antagonists reduce the elevated plasma
level of noradrenalin (NA) in mice with cardiac hypertrophy
Up-regulation of circulating 5-HT has been reported in
patients with hypertensive heart disease19, heart failure20 and
in rats with pressure-overload induced cardiac hypertrophy21.
Moreover, it has been reported that increase in plasma 5-HT is
responsible for valvular ﬁbrosis, ventricular dysfunction22,23
and promotes cardiac hypertrophy by pressure overload24.
Cardiac hypertrophy or congestive heart failure showssympathetic activation and increased plasma noradrenaline25,
which initiates cardiac hypertrophy and harmful consequences
in the myocardium26,27. Based on the evidence that activ-
ation of 5-HT3 receptors enhances noradrenaline release
12,13,
Rong Huo et al.20we hypothesize that blockade of 5-HT3 receptors would
decrease the elevated plasma NA. As shown in Fig. 5A,
plasma NA level increased in mice with pressure-overload
cardiac hypertrophy. Treatment with ondansetron or tropise-
tron reduced the increased plasma NA level. However,
ondansetron or tropisetron treatment did not change the
plasma NA level in normal mice (Fig. 5B).3.4. Tropisetron restores the desensitization of cardiac
b-adrenergic receptor in rat treated with abdominal aortic banding
The representative blood pressure recordings in sham, AB and
AB rats treated with tropisetron were shown in Figs. 6A–CFigure 6 The representative blood pressure recordings in sham, AB
were shown in (D) and (E). AB, abdominal aortic banding; TP, tr
##Po0.01 vs AB.and the summarized data were shown in Figs. 6D and E. As
expected, abdominal aortic banding was associated with a
signiﬁcant increase in systolic blood pressure and þdp/dtmax,
indicating a hypercontractile state as previously described28.
Administration of tropisetron restored the changes of 7dp/dt
but did not affect the increase of systolic blood pressure in
AB-treated rats. It has been reported that desensitization and
downregulation of b-adrenergic receptors occur before the
development of overt cardiac dysfunction29, we then examined
whether tropisetron restored the contractile response to
b-agonist stimulation in AB-treated rats. As shown in
Fig. 6E, administration of tropisetron signiﬁcantly attenuated
the decreased contractile response to b-agonist dobutamine
(0.8 mg/kg, iv) in AB-treated rats.and ABþTP rats were shown in (A–C) and the summarized data
opisetron; P, pressure. Po0.05, Po0.01 vs sham; #Po0.05,
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There is substantial evidence supporting that 5-HT induces
cardiac hypertrophy22,24,30 and the major mechanism is
through the activation of 5-HT2 receptor
31–34. Blockade of
5-HT2 receptor inhibits cardiac hypertrophy
33,35–37. Based on
the role of 5-HT3 receptor in activation of cardiac sympathetic
afferent9,10, we put forward the hypothesis that 5-HT3 recep-
tor might be a target for inhibition of sympathetic activation
and 5-HT3 receptor antagonists would protect against cardiac
hypertrophy. Here, we found that 5-HT3 receptor antagonists
protected against cardiac hypertrophy induced by pressure
overload in mice, restored the desensitization of b-adrenergic
receptors, and the mechanism might be through reducing the
sympathetic activity.
We used two kinds of 5-HT3 receptor antagonists, ondanse-
tron and tropisetron. Ondansetron and tropisetron showed
different structure with similar parent nucleus. Both ondanse-
tron and tropisetron inhibited pressure-overload induced cardiac
hypertrophy, reduced the elevated plasma level of noradrenalin
in cardiac hypertrophy mice, and had no direct inhibition on
in vitro cardiomyoctes hypertrophy. Compared with sham
group, the inhibitory effect of ondansetron and tropisetron on
cardiac hypertrophy was not complete (Figs. 1B–E), suggesting
that there were other factors in TAC-induced cardiac hyper-
trophy except the sympathetic activation.
In addition to protection against cardiac hypertrophy, the
beneﬁcial cardiovascular effects of 5-HT3 receptor antagonist
have been reported previously. 5-HT3 receptor antagonist
inhibits the 5-HT-induced cardiogenic hypertensive chemore-
ﬂex38, protects against cardiac arrhythmias without eliciting
hemodynamic side effects39, and regulates the autonomic
cardiac dysfunction in primary ﬁbromyalgia syndrome
patients40. The 5-HT3 receptors locate widely in the body,
including the central nervous system, peripheral nervous
system, and varieties of other cells. 5-HT3 receptors modulate
the release of neurotransmitters and neuropeptides, like
dopamine, acetylcholine, GABA, substance P10,41, therefore,
it is no doubt that the effects of activation or inhibition of
5-HT3 receptors are complex. Although we demonstrated that
5-HT3 receptor antagonists reduced the elevated plasma level
of noradrenalin in cardiac hypertrophy animals, we still could
not elucidate the exact action site of 5-HT3 receptor antago-
nists, which was the limitation of the present study.
It has been reported that AB treatment in rats induced
cardiac hypertrophy and desensitized cardiac adrenergic
responsiveness42. In the present study, we found that AB
treatment induced slight cardiac hypertrophy, but signiﬁcantly
reduced the cardiac adrenergic responsiveness, as shown in
Fig. 6 that the response of cardiac function to b-adrenergic
receptor agonist dobutamine was reduced in AB-treated rats.
Tropisetron restores the desensitization of b-adrenergic recep-
tor in AB-treated rats. The mechanism might be due to the
reduction of elevated plasma level of noradrenalin in cardiac
hypertrophy animals.
Heart failure, the result of cardiac hypertrophy, is a deadly
condition. Sympathetic activation is an important pathologi-
cal factor in promoting heart hypertrophy to heart failure.
Therefore, antagonism of sympathetic nervous system is a
valuable therapeutic method for cardiac hypertrophy and
heart failure. b-Adrenoceptor antagonists, for instance, carve-
dilol and nebivolol, are commonly used. In the present study,we found that 5-HT3 receptor antagonists, ondansetron and
tropisetron, protected against pressure-overload cardiac
hypertrophy. Both ondansetron and tropisetron reduced the
elevated plasma noradrenalin level in hypertrophic mice,
suggesting that the protective effects of 5-HT3 receptor
antagonists on hearts were due to their inhibition of sympa-
thetic activation. Unlike the direct adrenoceptor blockade,
5-HT3 receptor antagonists inhibit sympathetic nervous sys-
tem through an indirect way. 5-HT3 receptor antagonists are
clinically used in controlling the nausea and vomiting pro-
duced by cancer chemotherapy and show good tolerance43–45.
We propose that they might be novel type of potential drugs
for treatment of heart hypertrophy.
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